Harmony Biosciences Holdings (HRMY) Consolidated Net Income (2019 - 2026)

Harmony Biosciences Holdings has disclosed Consolidated Net Income across 8 years of filings, most recently posting $32.5 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at $32.5 million, down 28.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.2 million (down 12.04% YoY), and the FY2025 annual result was $173.3 million, down 0.94% from the prior year.
• Consolidated Net Income came in at $32.5 million for Q1 2026 at Harmony Biosciences Holdings, down from $37.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $87.9 million in Q3 2022 to a low of -$37.4 million in Q4 2022.
• The 5-year median for Consolidated Net Income is $37.1 million (2025), against an average of $35.6 million.
• Peak annual rise in Consolidated Net Income reached 1014.17% in 2022, while the deepest fall reached 296.42% in 2022.
• Harmony Biosciences Holdings' Consolidated Net Income stood at -$37.4 million in 2022, then jumped by 171.08% to $26.6 million in 2023, then surged by 196.69% to $78.9 million in 2024, then sank by 52.98% to $37.1 million in 2025, then fell by 12.46% to $32.5 million in 2026.
• The last three Consolidated Net Income figures came in at $32.5 million (Q1 2026), $37.1 million (Q4 2025), and $50.9 million (Q3 2025), per Business Quant data.